Penn Medicine – Abramson Cancer Center hared a post on X:
“A study from ASCO25 looked at using a ctDNA blood test to identify early signs that Breast Cancer was becoming resistant to Tx before showing up on other tests. Angie Demichele, who served as the study discussant in the ASCO Plenary Session, weighed in.”
Read Full Article on ASCO Daily News.
Read also OncoDaily’s Special Article: “ASCO 2025 Plenary Highlights: Key Practice-Changing Data Across TOP 5 ATOMIC, MATTERHORN, SERENA-6, VERIFY, and NIVOPOSTOP Trials”
